Not surprising for genetic aberrations in genes that have an adverse prognosis in stage IV melanoma [14–16], we also found that patients with APC/CTNNB1 genetic aberrations and stage IV melanoma have slightly higher incidence and earlier onset (i.e., within six months of diagnosis of MM) of MBMs compared to patients without APC/CTNNB1 genetic aberrations. The gene discussed is CTNNB1; the disease is Miyoshi myopathy.